Electronic monitor for patient compliance with drug therapy

1991 ◽  
Vol 29 (6) ◽  
pp. 607-608
Author(s):  
P. W. Nicholson
Keyword(s):  
Drug Therapy ◽  
Patient Compliance

Patient Compliance with Drug Therapy in Schizophrenia

2000 ◽  
Vol 18 (2) ◽  
pp. 105-124 ◽  
Author(s):  
Eva Lindström ◽  
Kerstin Bingefors
Keyword(s):  
Drug Therapy ◽  
Patient Compliance

scholarly journals ABC of monitoring drug therapy. Patient compliance.

BMJ ◽  
1992 ◽  
Vol 305 (6860) ◽  
pp. 1009-1011 ◽  
Author(s):  
J. K. Aronson ◽  
M. Hardman
Keyword(s):  
Drug Therapy ◽  
Patient Compliance ◽  
Monitoring Drug

A Study of Once Daily Tenormin (Atenolol) in Hypertension: Some Implications in Patient Compliance

1976 ◽  
Vol 4 (5) ◽  
pp. 347-351 ◽  
Author(s):  
A M Harris ◽  
K V Woollard ◽  
J A Tweed
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Clinical Study ◽  
Side Effects ◽  
Patient Compliance ◽  
Pressure Control ◽  
Once Daily ◽  
Hypertensive Patients ◽  
Significant Difference ◽  
Pre Treatment

A clinical study is described in which hypertensive patients on no drug therapy were given atenolol in increasing doses from 50 mg twice daily to 200 mg twice daily until the diastolic blood pressure was 90 mm Hg or below. At this stage the drug was withdrawn until blood pressure readings had risen to pre-treatment levels. The same dose of atenolol was then re-introduced but now given once-a-day (in the morning) and was continued for four weeks. Of the eleven patients entering the study, one withdrew as his blood pressure was not controlled on a dose of 200 mg of atenolol twice daily, and another because on withdrawal of atenolol his blood pressure did not rise to pre-treatment levels. The remaining nine patients completed the study. There was a statistically significant fall in blood pressure on both atenolol regimes and there was no significant difference between the blood pressure control achieved on twice-a-day and once-a-day administration. Only one patient developed side-effects; this being an asthmatic who developed mild dyspnoea on atenolol which did not necessitate withdrawal of the drug. It is concluded that once-a-day administration of a given dose of atenolol is therapeutically equivalent to twice-a-day administration. The implications of this in terms of better patient compliance, and thus better prognosis, are discussed.

scholarly journals Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux

Joints ◽  
2016 ◽  
Vol 04 (04) ◽  
pp. 214-221 ◽  
Author(s):  
Paolo Di Benedetto ◽  
Luigi Vetrugno ◽  
Dania De Franceschi ◽  
Renato Gisonni ◽  
Araldo Causero ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Patient Compliance ◽  
Subcutaneous Injection ◽  
Orthopaedic Surgery ◽  
Oral Anticoagulants ◽  
Subcutaneous Administration ◽  
Antithrombotic Drug ◽  
Major Orthopaedic Surgery ◽  
High Level ◽  
Very High

Purpose: the main purpose of our study was to compare patient compliance with the orally administered new oral anticoagulants (NOCs) dabigatran and rivaroxaban compared with subcutaneously injected fondaparinux after major orthopaedic surgery, and to assess patient preference for the oral vs subcutaneous administration route. Methods: prophylactic antithrombotic drug therapy with dabigatran (group D; GD, n=32 patients), rivaroxaban (group R; GR, n=38 patients) or fondaparinux (group F; GF, n=30 patients), to prevent deep vein thrombosis, was started immediately after surgery in 100 patients submitted to total hip arthroplasty. Results: the patients had a mean age of 68.7±11 years and 62% were female. In GD, 87.5% of patients indicated that they preferred oral intake of medications to subcutaneous injection (12.5%). In GR, 84.2% declared a preference for oral administration over subcutaneous injection (15.8%). In GF, a surprisingly high proportion of patients (73.3%; p < 0.001) declared that they preferred subcutaneous administration of medications over the oral route (26.7%). Overall, the rate of compliance with antithrombotic drug therapy was very high, at 99%. Conclusions: intake of the NOAs dabigatran and rivaroxaban following hospital discharge is entirely the responsibility of the patient; a high level of patient compliance with these drugs must therefore be demonstrated in order for them to become well accepted within the medical community. The results of this study showed a very high level of compliance both with orally and subcutaneously administered drugs. Level of evidence: Level I, randomized clinical study.

A device for the assessment of patient compliance to aerosol drug therapy

2003 ◽  
Author(s):  
D.R. Harrison ◽  
C.P. Burns ◽  
J.F. Hare ◽  
S.A. O'Connor
Keyword(s):  
Drug Therapy ◽  
Patient Compliance

Trial Data Suggest Value of Drug Therapy for Prehypertension

2006 ◽  
Vol 39 (7) ◽  
pp. 7
Author(s):  
BRUCE JANCIN
Keyword(s):  
Drug Therapy ◽  
Trial Data

Drug Therapy for ‘Prediabetes’ Held Premature

2009 ◽  
Vol 42 (7) ◽  
pp. 26
Author(s):  
MITCHEL L. ZOLER
Keyword(s):  
Drug Therapy
Sign in / Sign up

Export Citation Format

Share Document